CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating Activities
Net (loss) income	$ (3,484)	$ 9,064
Adjustments to reconcile net (loss) income to net cash from operating activities:
Depreciation and amortization	6,484	8,699
Amortization of debt issuance costs and Royalty Rights	147	28
Recurring fair value measurements of assets and liabilities	9,167	1,645
Debt-related expenses	9,918	0
Provisions for inventory and other assets	1,072	31
Stock-based compensation	2,446	982
Deferred income taxes	(1,367)	0
Changes in assets and liabilities, net of acquisition:
Accounts receivable	(1,109)	(4,561)
Inventories	(3,602)	(2,022)
Prepaid and other assets	1,824	9,845
Accounts payable and other accrued liabilities	(290)	(1,511)
Accrued rebates, returns and discounts	2,887	2,926
Interest payable	(1,376)	2,300
Net cash provided by operating activities	22,717	27,426
Investing Activities
Purchase of Sympazan	(105)	0
Purchase of Otrexup	0	(404)
Net cash used in investing activities	(105)	(404)
Financing Activities
Payment in settlement of convertible debt inducement	(10,500)	0
Payment of direct transaction costs related to convertible debt inducement	(1,119)	0
Payment of contingent consideration	(6,609)	(1,845)
Payment of taxes related to net share settlement of equity awards	(722)	(598)
Net cash used in financing activities	(18,950)	(2,443)
Net increase in cash and cash equivalents	3,662	24,579
Cash and cash equivalents at beginning of year	64,941	36,810
Cash and cash equivalents at end of period	68,603	61,389
Supplemental Disclosure of Cash Flow Information
Net cash paid (refunded) for income taxes	29	(8,360)
Cash paid for interest	$ 2,351	$ 0